Exosome Surface Modification Service with Aptamers

Aptamers—short single-stranded DNA or RNA oligonucleotides selected through the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) process—offer exceptional binding affinity and specificity toward a wide range of molecular targets. When conjugated to the exosome surface, aptamers transform native extracellular vesicles into precision-guided nanocarriers capable of receptor-targeted recognition, selective cellular uptake, and controlled cargo delivery.

At Creative Biostructure, we provide customized exosome surface modification service with aptamers, enabling researchers to engineer functionally enhanced exosomes for targeted delivery studies, biosensing applications, and preclinical therapeutic investigations. Our platform integrates aptamer design, validated conjugation chemistries, and rigorous characterization to ensure optimal biological performance.

Why Aptamer-Based Exosome Surface Modification

Although exosomes exhibit intrinsic biocompatibility and natural cellular communication capabilities, their native surface profiles often lack the targeting precision required for selective cell interaction. Aptamer functionalization addresses this limitation by providing programmable, high-affinity recognition elements that can be customized to virtually any surface antigen or receptor.

Key advantages of aptamer-modified exosomes include:

  • High binding affinity and specificity: Dissociation constants in the nanomolar to picomolar range against defined molecular targets
  • Low immunogenicity: Oligonucleotide-based ligands with minimal immune activation risk compared to antibodies
  • Chemical versatility: Amenable to diverse conjugation chemistries including cholesterol insertion, click chemistry, and biotin-streptavidin coupling
  • Customizable by design: Sequences engineered or selected to target specific biomarkers such as nucleolin, EpCAM, EGFR, PSMA, and MUC1
  • Scalable synthesis: Chemical synthesis enables high-purity, batch-consistent aptamer production without biological manufacturing
  • Stability: Chemical modifications (e.g., phosphorothioate backbones, 2′-F/OMe substitutions) enhance nuclease resistance

These properties make aptamer-based surface modification a compelling alternative and complement to antibody or peptide functionalization strategies in advanced exosome engineering.

Illustration of aptamer-functionalized exosomes used in targeted therapy for cancer treatment.Figure 1. Aptamer-Functionalized Exosome for Targeted Cancer Therapy. (Wu Y, et al., 2024)

Comparison of Exosome Surface Modification Strategies

Aptamer-based modification occupies a unique positioning among exosome engineering strategies:

Feature Aptamers Antibodies Peptides & Ligands
Molecular Size Small (6-30 kDa) Large (~150 kDa) Small (<5 kDa)
Target Specificity High (picomolar-nanomolar Kd) High Moderate-High
Immunogenicity Very Low Moderate Low
Tissue Penetration Good Limited Excellent
Stability High (with modification) Moderate High
Custom Selectability Yes (SELEX) Limited Limited

Our Aptamer Functionalization Strategies

We offer multiple validated aptamer conjugation and display platforms, each optimized for exosome integrity, functionalization efficiency, and downstream performance. Strategy selection is guided by aptamer type, target biology, and application requirements.

1. Cholesterol- or Lipid-Anchored Aptamer Insertion (Post-Insertion Method)

Aptamers conjugated with hydrophobic anchors (e.g., cholesterol, DSPE lipid tails) spontaneously intercalate into the exosome lipid bilayer under mild conditions. This approach preserves vesicle structure and biological activity while enabling efficient surface display.

  • Cholesterol-DNA/RNA aptamer post-insertion
  • DSPE-PEG-aptamer conjugate integration
  • Mild, aqueous-phase incubation protocol

Best for: Preserving exosome membrane integrity with controlled surface density

2. Covalent Chemical Conjugation

Aptamers are covalently attached to exosome membrane proteins or modified lipid head groups through well-characterized bioconjugation reactions, providing stable, long-lasting surface modification resistant to physiological conditions.

  • Click chemistry (azide–alkyne, DBCO–azide cycloaddition)
  • NHS-ester / EDC coupling to amine groups
  • Maleimide–thiol conjugation for site-specific attachment

Best for: Stable and reproducible covalent surface modification

3. Biotin-Streptavidin Bridge Coupling

Biotinylated aptamers are anchored to streptavidin pre-conjugated onto exosome surfaces via NHS-ester chemistry, enabling modular, high-affinity aptamer display. This strategy is widely used in biosensing and detection research.

  • Pre-functionalization of exosomes with streptavidin
  • High-affinity biotin–streptavidin binding (Kd ~10⁻¹⁵ M)
  • Supports multiplex aptamer display

Best for: Flexible, modular aptamer loading for detection and capture applications

4. RNA Nanotechnology-Based Display

Using RNA nanostructure design, aptamers are incorporated into engineered RNA scaffolds (e.g., arrowhead nanoparticles) that anchor to the exosome outer membrane via cholesterol or lipid tails, presenting aptamers in optimal orientations for target engagement.

  • Programmable RNA scaffold design with embedded aptamer modules
  • Precise control of aptamer orientation and density
  • Compatible with multivalent aptamer presentation

Best for: Structural precision and multivalent display studies

5. Hybrid Functionalization Strategies

Aptamer surface display can be combined with other exosome engineering approaches—including PEGylation, cargo loading, and membrane fusion—to create multifunctional exosome systems with tunable properties.

  • Aptamer + PEGylation for stealth and targeted delivery combination
  • Aptamer + siRNA/miRNA cargo co-loading
  • Dual aptamer display for multi-receptor targeting

Best for: Advanced research requiring simultaneous targeting, stealth, and cargo delivery

Representative Aptamers Supported

Aptamer Target Application Area
Sgc8 / TD05 PTK7 / CCRF-CEM (leukemia) Cancer cell-selective uptake
MUC1 aptamer MUC1 (breast, ovarian cancer) Targeted oncology research
EpCAM aptamer EpCAM (epithelial cancers) CTC detection, targeted delivery
PSMA aptamer PSMA (prostate cancer) Prostate cancer targeting
CL4 aptamer EGFR NSCLC, TNBC research
hBS01 Transferrin receptor (BBB transport) CNS drug delivery research
CD63 aptamer Exosome surface protein CD63 Exosome capture, EAA loading
Custom / SELEX-derived Client-defined target Any receptor or biomarker

Service Workflow

1

Consultation & Target Assessment

Evaluate receptor biology, aptamer options, and project goals, with feasibility and experimental design recommendations.

2

Aptamer Selection & Validation

Select literature-validated aptamers or initiate custom SELEX, confirming binding affinity.

3

Conjugation Strategy Design

Optimize surface modification based on aptamer structure, exosome source, and application.

4

Exosome Production or Sample Assessment

Produce exosomes from cell lines or assess client samples for quality and compatibility.

5

Aptamer Surface Modification & Purification

Execute conjugation under optimized conditions, removing unconjugated aptamers and byproducts.

6

Characterization & Delivery

Verify modified exosomes and provide delivery with full documentation and technical support.

Workflow showing six steps of aptamer-based exosome surface modification, from consultation to delivery.Figure 2. Workflow of Exosome Surface Modification Service with Aptamers. (Creative Biostructure)

Characterization and Quality Control

We provide multi-dimensional analytical validation to confirm successful aptamer surface modification and maintain exosome integrity:

  • Particle size and size distribution: NTA (nanoparticle tracking analysis) and DLS (dynamic light scattering)
  • Morphology analysis: TEM (transmission electron microscopy) or Cryo-EM
  • Zeta potential measurement: Surface charge assessment before and after modification
  • Aptamer surface display confirmation: Fluorescence-labeled aptamer tracking, flow cytometry
  • Aptamer copy number quantification: Fluorescence quantification or mass spectrometry-based analysis
  • Binding affinity verification: EMSA, SPR, or cell-based binding assays with target-positive and target-negative controls
  • Cellular uptake and internalization studies: Confocal microscopy, flow cytometry with relevant cell models
  • Exosome protein marker validation: Western blot (CD9, CD63, CD81, TSG101) to confirm vesicle identity
  • Stability testing: Colloidal stability in physiological buffers; nuclease resistance testing (where applicable)

Applications of Aptamer-Modified Exosomes

Aptamer-functionalized exosomes support a broad spectrum of research applications where high targeting precision and programmable surface chemistry are essential:

Application Area Description
Targeted Cancer Therapy Research Receptor-specific delivery of chemotherapeutics, siRNA, or miRNA to tumor cells expressing EpCAM, MUC1, EGFR, or PSMA
Blood-Brain Barrier (BBB) Transport Studies Aptamer-guided exosome transcytosis across the BBB using transferrin receptor-targeting aptamers for CNS drug delivery research
Nucleic Acid Therapeutics Delivery Loading and targeted delivery of siRNA, antisense oligonucleotides (ASO), PMO, and miRNA via aptamer-cargo co-loading strategies
Liquid Biopsy & Biosensing Aptamer-functionalized exosomes or surfaces for capture and detection of disease-specific exosomes from clinical samples (serum, plasma, urine)
Immunotherapy Support Aptamer-guided delivery of immune-modulating payloads; investigation of aptamer-exosome platforms in checkpoint inhibitor combination strategies
Cell-Type Selective Interaction Studies Investigation of receptor-mediated endocytosis and intracellular trafficking in defined cell populations

How to Start Your Project

We provide flexible project initiation options to accommodate different research scenarios. You may choose to provide your own exosomes and/or aptamers, or engage our end-to-end service.

Project Initiation Options

Option Description Best For What You Need to Provide
Client-Provided Exosomes & Aptamer We perform surface modification using your supplied exosome samples and aptamer sequences or molecules. Researchers with established exosome systems or proprietary aptamers
  • Exosome source, isolation method, concentration, and buffer
  • Aptamer sequence, format (DNA/RNA), and any existing modifications
  • Target receptor information
Client-Provided Aptamer Only We produce exosomes in-house and execute aptamer surface modification per your specifications. Researchers with characterized aptamers but without dedicated exosome production
  • Aptamer sequence and format
  • Preferred exosome cell source
  • Application goals
End-to-End Service (Recommended) Full workflow: exosome production, aptamer selection or sourcing, surface modification, and comprehensive validation. Researchers seeking a turnkey solution with minimal experimental burden
  • Target receptor or cell type
  • Application objectives
  • Specific experimental requirements

Quick Project Kickoff Requirements

Information Type Details
Target Information Target receptor, cell type, or disease model of interest
Aptamer Information Known aptamer (if available) or target description for selection/recommendation
Application Goal Targeted uptake, cargo delivery, biosensing, BBB research, etc.
Exosome Source Cell line of origin, isolation method, concentration (if client-provided)
Special Requirements Specific conjugation chemistry preference, QC assays, or downstream use conditions

What Deliverables Will You Receive

Our service provides clearly defined, research-ready deliverables to support reproducibility, validation, and downstream applications:

Category Description
Aptamer-Modified Exosome Samples Surface-functionalized exosomes with defined aptamer type, particle concentration, volume, and storage conditions
Aptamer Surface Display Confirmation Fluorescence-based tracking or biochemical assay data confirming aptamer conjugation and surface density
Physicochemical Characterization Size distribution (NTA/DLS), morphology (TEM), zeta potential, and purity assessment
Functional Evaluation (Optional) Comparative cellular uptake analysis of aptamer-modified vs. unmodified exosomes in target cell models
Methods & Protocol Summary Detailed conjugation strategy, key experimental parameters, and aptamer source/sequence information
Project Report Consolidated results, data interpretation, QC assessment, and technical insights
Technical Support Post-delivery consultation for downstream applications, troubleshooting, and experimental guidance

Why Choose Creative Biostructure

  • Expertise in exosome engineering with validated modification platforms
  • Extensive aptamer library, including Sgc8, EpCAM, PSMA, MUC1, and custom sequences
  • Multiple conjugation strategies tailored to project needs
  • Rigorous quality control ensuring vesicle integrity
  • Flexible project models: partial or full turnkey solutions
  • Scalable workflows for exploratory and preclinical research

Case Study

Case: Aptamer-Functionalized Exosomes for Targeted Doxorubicin Delivery in Colorectal Cancer

Background

Doxorubicin (DOX) suffers from poor targeting and severe side effects. This study developed aptamer-functionalized exosomes (DOX-Apt-Exo) for targeted delivery to nucleolin-expressing colorectal cancer cells.

Methods

HEK-293-derived exosomes were loaded with DOX and functionalized with aptamer using EDC/NHS chemistry. Characterization was done via DLS, TEM, and flow cytometry.

Results

  • In vitro: DOX-Apt-Exo showed enhanced uptake and lower cytotoxicity compared to non-targeted exosomes.
  • In vivo: DOX-Apt-Exo reduced tumor size by 65%, significantly outperforming free DOX (72%) and non-targeted DOX-Exo.
  • Biodistribution: Exosomes accumulated at tumor sites, with minimal uptake in non-target tissues.

Conclusion

Aptamer-functionalized exosomes enhance DOX delivery and efficacy, providing a safe and effective solution for targeted cancer therapy.

Ex vivo optical images showing the biodistribution and retention of FAM-labeled AS1411 aptamer-exosomes in tumor, lung, liver, heart, and kidneys at 1, 8, 24, and 48 hours post-injection in tumor-bearing mice. Red circles indicate tumor sites.Figure 3. In Vivo Biodistribution of FAM-Labeled Aptamer-Functionalized Exosomes in Tumor-Bearing Mice. (Hosseini N F, et al., 2022)


Design aptamer-functionalized exosomes tailored to your specific research targets and delivery objectives. Our team will develop a custom engineering strategy optimized for your application, from aptamer selection to functional validation. Contact us to discuss your project and receive a personalized proposal.

References

  1. Hosseini N F, Amini R, Ramezani M, et al. AS1411 aptamer-functionalized exosomes in the targeted delivery of doxorubicin in fighting colorectal cancer. Biomedicine & Pharmacotherapy. 2022, 155: 113690.
  2. Han G, Zhang Y, Zhong L, et al. Generalizable anchor aptamer strategy for loading nucleic acid therapeutics on exosomes. EMBO Molecular Medicine. 2024, 16(4): 1027.
  3. Wu Y, Cao Y, Chen L, et al. Role of exosomes in cancer and aptamer-modified exosomes as a promising platform for cancer targeted therapy. Biological Procedures Online. 2024, 26(1): 15.

Frequently Asked Questions

For any inquiries, our support team is ready to help you get technical support for your research and maximize your experience with Creative Biostructure.

Online Inquiry
Online Inquiry
For Research or Industrial Raw Materials, Not for Personal Use!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Our Valued Partnerships

Poster Download

x